Last week, the Adamis Pharmaceuticals (NASDAQ:ADMP) stock had performed quite strongly and managed to clock gains of 45%. However, the situation has reversed somewhat this week and this morning the Adamis stock has declined by 8%.
Yesterday, the stock had jumped after it was announced that Adamis’ product Tempol has been identified as a potential treatment for COVID 19 patients by the National Institutes of Health. As per the study that had been conducted on cell structures, it was noticed that Tempol could help in limiting COVID 19 infection.
In this regard, it should also be noted that the researcher have also revealed that they are also going have further studies and eventually Tempol is going to be evaluated in a clinical study. Earlier on in the month the company had announced that it was making preparations for a Type A meeting with the United States Food and Drug Administration regarding its New Drug Application for the opioid overdose treatment product ZIMHI.
Moving Averages
| +/- EMA(20) | 0.84 (+21.43%) |
| +/- SMA(50) | 0.81 (+25.93%) |
| +/- SMA(200) | 0.83 (+22.89%) |
Technical Indicators
| Symbol | Value | Result | Symbol | Value | Result |
| ADX | 23.5179 | Neutral | ATR14 | 0.1251 | |
| CCI20 | 268.3693 | OverBought | Chaikin Money Flow | 0.3253 | Buy |
| MACD | 0.0309 | Buy | Money Flow Index | 73.9050 | Buy |
| ROC | 39.7764 | Buy | RSI | 63.3009 | Buy |
| STOCH (14,3) | 75.2066 | Buy | STOCH RSI | 0.7442 | Buy |
| UO | 60.8188 | Buy | Williams %R | -24.7934 | Neutral |
 stock Slips Below $1: Is A Bounce Coming?){kind=link}